Breast Cancer Now Catalyst Programme Grants Apply now
We are inviting Expressions of Interest from researchers who are interested in using Pfizer drugs for preclinical or clinical breast cancer research from teams based at a single site or multiple sites in the UK and Europe. To apply please visit our website.
TABLE OF CONTENTS
Volume 116, Issue 5 (553-696) Published online 28 February 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, Richard S Finn, Zev A Wainberg, Daniel A Laheru, Colin D Weekes, Benjamin R Tan, Gazala N Khan, Mark M Zalupski, Jeffrey R Infante, Suzanne Jones, Kyriakos P Papadopoulos, Anthony W Tolcher, Renae E Chavira, Janna L Christy-Bittel, Emma Barrett and Amita Patnaik
Br J Cancer 2017 116: 575-583; advance online publication, February 2, 2017; 10.1038/bjc.2017.10
MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma
Nuno André Padrão, Sara Monteiro-Reis, Jorge Torres-Ferreira, Luís Antunes, Luís Leça, Diana Montezuma, João Ramalho-Carvalho, Paula C Dias, Paula Monteiro, Jorge Oliveira, Rui Henrique and Carmen Jerónimo
Br J Cancer 2017 116: 634-639; advance online publication, January 12, 2017; 10.1038/bjc.2016.454
Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups
Elias Sundquist, Joonas H Kauppila, Johanna Veijola, Rayan Mroueh, Petri Lehenkari, Saara Laitinen, Juha Risteli, Ylermi Soini, Veli-Matti Kosma, Iris Sawazaki-Calone, Carolina Carneiro Soares Macedo, Risto Bloigu, Ricardo D Coletta and Tuula Salo
Br J Cancer 2017 116: 640-648; advance online publication, January 17, 2017; 10.1038/bjc.2016.455
Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription.
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).